Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

サイズ 価格(税別)  
JPY 46800
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells M1zGTWN6fG:2b4jpZ:Kh[XO|YYm= MoP4OFghcA>? MkPQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUTlMVA3KM7:TT6= MWOyNVM5QDF7MR?=
human colon cancer cell line (LoVo cells) NVXmUnh6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIfYOHRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v M4HnR|EyPTlzNUC1
human LoVo cells NX;Y[I0zWHKxbHnm[ZJifGmxbjDhd5NigQ>? MYO0PEB1dyB5MjDo NYja[GR[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[Xl? MWOyNlE5Ojl{OR?=
P19 cells M4HmdmZ2dmO2aX;uJIF{e2G7 MlHoTY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgdoVk\XC2b4KgbY4hWDF7IHPlcIx{NCCLQ{WwQVAvODB{IN88UU4> NFPHNGEyPTd5MUSxPS=>
human BJ cells NH;XOohEgXSxdH;4bYPDqGG|c3H5 MVK3NkBp Ml7LR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPhcINmcW5iQV2gZZN{[XluIFnDOVA:OC5yMEKg{txONg>? NWLmPXVLOjJ7MkGwPFE>
human HT-29 cells NVLXTIlzTnWwY4Tpc44h[XO|YYm= NWHSblVJOiCq MX7F[oZm[3Rib36gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyb4TlcpRq[WxiaX6gbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiMjDodpMhfXOrbnegTmMuOSC|dHHpcolv\yCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYm= NWTDdJk6OjF2MkizO|U>
human A549 cells NX\hN3Q1S3m2b4TvfIlkyqCjc4PhfS=> MnL0O|IhcA>? NUjUbFRNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBu\XSqb3S= MkLPNVg1QDR5N{W=
human HT-29 cells MXfGeY5kfGmxbjDhd5NigQ>? NWXWfHZKUW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCxdHXueIlidCCrbjDoeY1idiCKVD2yPUBk\WyuczD1d4lv\yCMQ{Gg[JlmKHO2YXnubY5oKGK7IH\seY9z\XOlZX7j[UBxdGG2ZTDy[YFl\XJiYYPzZZktKEmFNUC9Nk42KG6P M2Dh[FIyPTF|Mkmz
human HT-29 cells MWXGeY5kfGmxbjDhd5NigQ>? MUKyJIg> MlrlTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDy[YR2[3Srb36gc4YhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDwc5RmdnSrYXygZYZ1\XJiMjDodpMh[nlidYPpcochUkNzIIP0ZYlvcW6pIHL5JIZtfW:{ZYPj[Y5k\SClZXzsMYJie2WmIHHzd4F6NCCHQ{WwQVIvPiCwTT6= NVHRR2ZHOjF7N{OxNFE>
Sf9 cells MUHGeY5kfGmxbjDhd5NigQ>? NVLhbVhSUW6qaXLpeIlwdiCxZjDoeY1idiCVeXug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0{KG6PLh?= MmfmNVg5OjN5OES=
human HUVEC NVLOOoxNWHKxbHnm[ZJifGmxbjDhd5NigQ>? M1vK[VQ5KHSxIEeyJIg> M3nCTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGXWSWMh[W[2ZYKgOFghfG9iN{KgbJJ{KGK7IF3UWEBie3OjeR?= NFW3dIszOjF6MkmyPS=>
P19 cells NEjNbItHfW6ldHnvckBie3OjeR?= NFXlVHdKdmirYnn0bY9vKG:oIGDyc5RmcW5iS3nuZZNmKEFiaX6gVFE6KGOnbHzzMEBKSzVyPUSgcm0v Mn;LNVU4PzF2MUm=
Sf9 cells NGSyZnBHfW6ldHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgcYlvKGK7IFXMTXNCKGmwIIDy[ZNmdmOnIH;mJFEhfW2xbD;MJGFVWA>? Mkj1NVc{OTV6NUO=
Sf21 cells M{\0ZmZ2dmO2aX;uJIF{e2G7 MkjMTY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u NHfudVAyPzB6OEC1PS=>
human colon carcinoma cell line HCT116 M3W5[WZ2dmO2aX;uJIF{e2G7 MkT5R49v[2WwdILheIlwdiC{ZYH1bZJm\CCob4Kg[5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwhdGmwZTDIR3QyOTZuIFnDOVA:PiCwTT6= MXSxOVU{PzN2NR?=
human ST486 cells NVrEd3lKWHKxbHnm[ZJifGmxbjDhd5NigQ>? M{DycFQ5KHSxIEeyJIg> MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOWNEi2JINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{BvVS5? MYOyNlE5Ojl{OR?=
human MDA-MB-231 cells MXrDfZRwfG:6aXRCpIF{e2G7 NFvR[|k4OiCq MlTjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCvZYToc4QtKEeLNUC9O{4yKG6PLh?= NWGxTHRCOTh2OES3O|U>
P19 cells NX\QbHpYTnWwY4Tpc44h[XO|YYm= NEH3T2lKdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v NX7FXmU5OTV5N{G0NVk>
human DLD1 cells NVm2Z3h2WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIjaPI01QC15MjDo NELWeIZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTMSFEh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF06KG6PLh?= NHHmTmwzOjF6MkmyPS=>
insect cells MlqzSpVv[3Srb36gZZN{[Xl? M3r6RmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUHntNUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIJ6KEiWUl[sJGlEPTB;MUCgcm0v NEfJTlkyQTF5OUC3Oi=>
V79 MZ cells MkL3SpVv[3Srb36gZZN{[Xl? M2DUUGlvcGmkaYTpc44hd2ZiaIXtZY4h[Wymb4P0[ZJwdmVic4nueIhie2ViZYjwdoV{e2WmIHnuJHY4QSCPWjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGGuZH;zeIVzd26nIIP5cpRp\XOrczygTWM2OD1zMTDuUU4> M4HzRVI1PDJ{NUG5
P19 cells MWXGeY5kfGmxbjDhd5NigQ>? M1XYUWlvcGmkaYTpc44hd2ZiVnHzZ5Vt[XJiZX7kc5Rp\WyrYXyg[5Jwf3SqIH\hZ5RweiC{ZXPldJRweiCrbjDQNVkh[2WubIOsJGlEPTB;MUSgcm0v NFnDT2gyPTd5MUSxPS=>
Sf9 cells MX3GeY5kfGmxbjDhd5NigQ>? MlPBNlAhdWmwcx?= MVvJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEKwJI1qdnNiYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSSLDDJR|UxRTF3IH7NMi=> MV2xO|MyPTh3Mx?=
human PBMC M4H5ZWZ2dmO2aX;uJIF{e2G7 M2L6ZlI1KGh? M2HwUHN2eHC{ZYPzbY9vKG:oIFnMNkBxem:mdXP0bY9vKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE3KG6PLh?= NG[5b2UyQDV6NUC0Oi=>
human A549 cells NV7ZU5I6S3m2b4TvfIlkyqCjc4PhfS=> M2P5ZVQ5KGh? NWjJWohJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6KCxiSVO1NF0zOCCwTT6= MmrpNlU5OjV7M{S=
human CEM cells NVHheI9tS3m2b4TvfIlkyqCjc4PhfS=> MkjpO|IhcA>? Mkn0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTJ|IH7NMi=> M{GzT|IzQTJzMEix
human HeLa cells M2rY[mN6fG:2b4jpZ:Kh[XO|YYm= M13VU|Q5KGh? MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MkWgcm0v NGLxTWozPTh{NUmzOC=>
human PC3 cells MYnDfZRwfG:6aXRCpIF{e2G7 NIq0Sms1QCCq MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTCsJGlEPTB;M{Ggcm0v Ml\mNlU5OjV7M{S=
human SF268 cells NH\ZVVREgXSxdH;4bYPDqGG|c3H5 Ml3JOFghcA>? Mn\MR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME20OEBvVS5? MoPvNlE2OTN{OUS=
human MCF7 cells MXzDfZRwfG:6aXRCpIF{e2G7 NHX6W|Y1QCCq NUC4bZN2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUxKG6PLh?= NVWx[VdoOjF|OEixPVE>
HEK293 cells MUHDfZRwfG:6aXRCpIF{e2G7 MlnHO|IhcA>? NVnGVm5SS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v MY[yOFc3OzJ4Mh?=
HUE cells M16yR2Z2dmO2aX;uJIF{e2G7 M1;RXVkxKG2rboO= NFHYVnFKdmirYnn0bY9vKG:oIG\FS2ZTOiCrbjDIWWUh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC2cnXheIVlKG[xcjC5NEBucW6|IHLl[o9z\SCYRVfGJINp[WyuZX7n[UBjgSCHTFnTRUwhUUN3ME23NEBvVS5? M{\V[VIxOTdyMU[z
human A431 cells M2HjdmN6fG:2b4jpZ:Kh[XO|YYm= NV3hWmE1OjRiIHi= M4fDN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh[W[2ZYKgNlQhcHK|IIXzbY5oKEGwbnX4bY4hXmWISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZpkhVVSWIHHzd4F6NCCLQ{WwQVcxKG6PLh?= MmX4NlI2PDFyNUG=
human Jurkat cells MVPQdo9tcW[ncnH0bY9vKGG|c3H5 MmnoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDKRWs{KGW6cILld5NqdmdiSVyyMZN1cW23bHH0[YQhcHWvYX6gTpVzc2G2IHPlcIx{NCCLQ{WwQVcyKG6PLh?= NWfWbndLOTl2MkeyNFM>
HEK293 cells NHXKOHdHfW6ldHnvckBie3OjeR?= MUXJcohq[mm2aX;uJI9nKEmOLUigdoVt\WG|ZTDifUBJTUt{OUOgZ4VtdHNiZYjwdoV{e2mwZzDQT2Mu[mW2YUKsJGlEPTB;N{egcm0v MlnBNVU4PzF2MUm=
human KE-97 cells MXXDfZRwfG:6aXRCpIF{e2G7 MnHMO|IhcA>? M{TyWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtGNTl5IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0doUuT2yxIHz1cYlv\XOlZX70JINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTNizszNMi=> MoXXNlQ{Ojh{OEO=
human CHOK1 cells MYPDfZRwfG:6aXRCpIF{e2G7 M1HBXlQ5KGh? MmG0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> NHPZU4czOTVzM{K5OC=>
mouse NIH/3T3 cells M3rXRWN6fG:2b4jpZ:Kh[XO|YYm= MVO5OkBp NVLl[GRIS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v M3zteVI1OzZzNUKx
human A2780 cells MlK1R5l1d3SxeHnjxsBie3OjeR?= NHXqfow6PiCq MnzBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NHTKTXAzPDN4MUWyNS=>
human 8505C cells MmPtR5l1d3SxeHnjxsBie3OjeR?= NFnIXJg6PiCq MmTNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= MUKyOFM3OTV{MR?=
human 518A2 cells NY\BN492S3m2b4TvfIlkyqCjc4PhfS=> MmH0PVYhcA>? NHTNSGREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5{IN88UU4> MknYNlQ{PjF3MkG=
human HuH7 cells M{PIXWN6fG:2b4jpZ:Kh[XO|YYm= NED6SpI4OiCq MknIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTJVJPyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{KM7:TT6= NFfQdpMzPDN{OEK4Ny=>
FL5.12-Akt1 cells MWTQdo9tcW[ncnH0bY9vKGG|c3H5 M1;3WWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmw2NjF{LVHreFEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjlizszNMi=> NEHsS2cyPjRyM{[yOi=>
human MiaPaCa-2 cells M{W1Z3Bzd2yrZnXyZZRqd25iYYPzZZk> NVLrNm9[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNbYFR[UOjLUKgZ4VtdHNuIFnDOVA:OC5|NzFOwG0v MXWxOlQyOzd6MB?=
human BGC823 cells M2L6WmN6fG:2b4jpZ:Kh[XO|YYm= MnqwO|IhcA>? M4XEbGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6IN88UU4> MWGyOFMzQDJ6Mx?=
human MCF7 cells MmGwR5l1d3SxeHnjxsBie3OjeR?= MXq5OkBp NVroVpV2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPCEQvF2u M1PFO|I1OzZzNUKx
human A549 cells NHruUo1EgXSxdH;4bYPDqGG|c3H5 NIHhc4Y6PiCq NUH3cWhvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u NGX1W4szPDN4MUWyNS=>
HEK293 cells NWPE[WY4S3m2b4TvfIlkyqCjc4PhfS=> MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBJTUt{OUOgZ4VtdHNuIFXDOVA:OiEQvF2u MWqyOVMyPjNzNx?=
human Raji cells  MXLDfZRwfG:6aXRCpIF{e2G7 NEnqd|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{NCCHQ{WwQVIh|ryPLh?= M2C3SFI2OzF4M{G3
human HepG2 cells MkTzR5l1d3SxeHnjxsBie3OjeR?= MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whTUN3ME2yJO69VS5? NHzkUnczPTNzNkOxOy=>
human BJ cells M1jNZ2N6fG:2b4jpZ:Kh[XO|YYm= Ml\UR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v NInHeZIzPTNzNkOxOy=>
human U937 cells NGHIU5dEgXSxdH;4bYPDqGG|c3H5 M3nDOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU6OzdiY3XscJMtKEmFNUC9NkDPxE1w MmDXNVcxQDhyNke=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-Akt / Akt / PARP /Cleaved PARP; 

PubMed: 24174874     


Western blot analysis for Akt, P-Akt, and cleaved poly(ADP-ribose) polymerase. U87 cells were incubated with 200 nM, 10 nM, and 0.1 nM of staurosporine encapsulated in liposomes and staurosporine for 32 hours.

FAK / RIP; 

PubMed: 15121855     


Western blot (WB) analysis of BT-20 and BT-474 lysates treated with staurosporine (200 nM). Control cells were treated with dimethyl sulfoxide for 18 h.

Ambra1; 

PubMed: 24587252     


SW620 cells treated with various doses of staurosporine for 6 h. Ambra1 levels were measured by Western blot. 

24174874 15121855 24587252
Growth inhibition assay
Cell viability; 

PubMed: 25215174     


Staurosporine reduces cerebellar astrocytes viability. (a) Cerebellar astrocytes were treated with staurosporine 0.1 μM, 0.25 μM, and 0.5 μM for 24 h and the cell viability was measured by MTT transformation. (b) Cerebellar astrocytes were treated with staurosporine 0.5 μM for 6, 12, and 24 h and the cell viability was measured by MTT transformation. Data are presented as mean ± SEM of four independent experiments. ∗ is significantly different from control (P < 0.05).

25215174
Immunofluorescence
Tubulin / Actin; 

PubMed: 25215174     


Morphological changes of astrocytes induced by St are evidenced by the rearrangement of cytoskeletal proteins. Astrocytes were treated with St (0.5 μM) for 12 hours and then were labelled with rhodamine-phalloidin or immunostained for tubulin. Representative images of phase contrast, rhodamine-phalloidin, and tubulin are shown in control and St treated astrocytes. Scale bar represents 50 μm.

Phalloidin / Type II collagen; 

PubMed: 22684244     


Cell were cultured in the absence (a-f) or presence of staurosporine (STSN, 5 × 10-9M) or cytochalasin D (CD, 1 µg/ml) for 1 (upper panel) or 2 (lower panel) days at low density and stained for F-actin (Phalloidin) and type II collagen (Type II). STSN: Staurosporine.

Pyk2; 

PubMed: 19880522     


Pyk2 translocates to the nucleus upon staurosporine addition to ID8 cells. Confocal immunofluorescent analysis of endogenous Pyk2 upon DMSO (control) or 1 μm staurosporine addition for 2 h. The scale bar is 10 μm. 

Annexin; 

PubMed: 15140398     


Induction of apoptosis with staurosporine resulting in activation of the ICE-NIRF probe. Gli36 cells were treated with 50 µM staurosporine for 24 hours (A-C) or with the same percentage of DMSO (0.01%) to which experimental wells were exposed (D-488nm laser, E-633nm laser and F-bright field). To examine the role of caspase-1 in staurosporine-induced apoptosis and probe activation, cells were coincubated in caspase-1 inhibitor (10 µM) and staurosporine (G-I). Staurosporine induces apoptosis, indicated by the positive annexin staining viewed with the 488-nm laser (A), which colocalized with activated probe viewed with the 633-nm laser (B). Coincubation of the caspase-1 inhibitor with staurosporine did not completely block apoptosis, indicated by the relatively higher number of apoptotic cells stained with annexin (G), as those that activated the probe (H). Magnification, x 40; scale bar, 50 µM.

cleaved-caspase 3; 

PubMed: 19840952     


Representative images (×1000 magnification) showing vehicle treated (C) and staurosporine treated (D) cells stained with anti-cleaved caspase 3 antibody and DAPI.

FAK 4.47; 

PubMed: 15121855     


BT-20 or BT-474 cell culture were plated on six-well plates and were treated with staurosporine (200 nM) after 24 h. After 6 h of treatment, cells were immunostained with anti-FAK 4.47 antibody (white arrowheads mark some focal adhesions).

25215174 22684244 19880522 15140398 19840952 15121855
体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
in solvent
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PKCシグナル伝達経路

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID